Two Sigma Investments LP Boosts Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Two Sigma Investments LP lifted its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 66.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 352,034 shares of the biotechnology company's stock after buying an additional 140,457 shares during the quarter. Two Sigma Investments LP owned about 1.16% of AnaptysBio worth $4,661,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also bought and sold shares of ANAB. Sanofi bought a new position in AnaptysBio in the 4th quarter valued at about $10,882,000. Rafferty Asset Management LLC boosted its stake in shares of AnaptysBio by 83.2% in the 4th quarter. Rafferty Asset Management LLC now owns 70,883 shares of the biotechnology company's stock worth $938,000 after buying an additional 32,185 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of AnaptysBio by 21.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,012 shares of the biotechnology company's stock valued at $199,000 after acquiring an additional 2,701 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of AnaptysBio by 85.3% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 85,381 shares of the biotechnology company's stock valued at $1,130,000 after acquiring an additional 39,307 shares during the last quarter. Finally, Graham Capital Management L.P. bought a new stake in AnaptysBio during the fourth quarter worth $251,000.

AnaptysBio Price Performance

NASDAQ:ANAB traded down $0.11 during trading hours on Friday, reaching $22.45. The company had a trading volume of 683,007 shares, compared to its average volume of 611,002. The firm has a market cap of $659.58 million, a PE ratio of -3.69 and a beta of -0.20. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $41.31. The business's 50 day moving average price is $19.65 and its 200-day moving average price is $18.26.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. The business had revenue of $27.77 million during the quarter, compared to analyst estimates of $15.27 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its board has approved a stock buyback program on Monday, March 24th that allows the company to repurchase $75.00 million in shares. This repurchase authorization allows the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

ANAB has been the subject of several recent research reports. Wedbush reissued an "outperform" rating and issued a $40.00 price objective on shares of AnaptysBio in a report on Thursday. Wolfe Research began coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price objective for the company. Johnson Rice restated a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th. HC Wainwright reaffirmed a "neutral" rating and issued a $22.00 price target on shares of AnaptysBio in a report on Tuesday, March 4th. Finally, Guggenheim reiterated a "buy" rating and set a $90.00 price objective (up from $54.00) on shares of AnaptysBio in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.38.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.